176
Participants
Start Date
January 25, 2021
Primary Completion Date
December 31, 2026
Study Completion Date
January 15, 2028
BI-1808
BI-1808 administered as a flat-dose IV infusion once every 3 weeks
Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.
ACTIVE_NOT_RECRUITING
PRA Health Sciences - Hungary, Budapest
RECRUITING
Magyar Honvédség-Egészségügyi Központ, Budapest
RECRUITING
Herlev Hospital, Herlev
RECRUITING
Debreceni Egyetem Klinikai Központ, Debrecen
RECRUITING
Karolinska University Hospital, Solna, Stockholm
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Sahlgrenska University Hospital, Gothenburg
RECRUITING
City of Hope National Medical Center, Duarte
WITHDRAWN
National Medical Research Center VA Almazov, Saint Petersburg
WITHDRAWN
N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg
TERMINATED
Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser, Omsk
RECRUITING
Rigshospitalet, Copenhagen
RECRUITING
The Royal Marsden Hospital NHS Foundation Trust, London
RECRUITING
Skanes University Hospital, Lund
RECRUITING
University Hospitals of Leicester NHS Trust, Leicester
RECRUITING
Guy's and Saint Thomas' NHS Foundation Trust, London
RECRUITING
Sarah Cannon Research Institute UK, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
Southampton General Hospital, Southampton
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
BioInvent International AB
INDUSTRY